These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 28242752)

  • 1. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline
    de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA
    Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
    Dhawan MS; Bartelink IH; Aggarwal RR; Leng J; Zhang JZ; Pawlowska N; Terranova-Barberio M; Grabowsky JA; Gewitz A; Chien AJ; Moasser M; Kelley RK; Maktabi T; Thomas S; Munster PN
    Clin Cancer Res; 2017 Nov; 23(21):6400-6410. PubMed ID: 28790114
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
    Naito Y; Kuboki Y; Ikeda M; Harano K; Matsubara N; Toyoizumi S; Mori Y; Hori N; Nagasawa T; Kogawa T
    Invest New Drugs; 2021 Dec; 39(6):1568-1576. PubMed ID: 34160752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
    Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 7. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    Litton JK; Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Quek RGW; Markova D; Tudor IC; Hannah AL; Eiermann W; Blum JL
    N Engl J Med; 2018 Aug; 379(8):753-763. PubMed ID: 30110579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
    McCann KE
    Future Oncol; 2019 May; 15(15):1707-1715. PubMed ID: 30912451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline
    Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke EM; Mina LA; Balmaña J; Fasching PA; Hurvitz SA; Wardley AM; Chappey C; Hannah AL; Robson ME;
    Clin Cancer Res; 2019 May; 25(9):2717-2724. PubMed ID: 30563931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
    J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
    Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
    J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
    Ettl J; Quek RGW; Lee KH; Rugo HS; Hurvitz S; Gonçalves A; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Markova D; Bhattacharyya H; Hannah AL; Eiermann W; Blum JL; Litton JK
    Ann Oncol; 2018 Sep; 29(9):1939-1947. PubMed ID: 30124753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
    Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
    Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
    [No Abstract]   [Full Text] [Related]  

  • 14. Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.
    Elmeliegy M; Yu Y; Litton JK; Czibere A; Wilson GG; Tudor IC; Zheng J; Wang DD
    J Clin Pharmacol; 2020 Oct; 60(10):1334-1343. PubMed ID: 32468645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline
    Litton JK; Scoggins ME; Hess KR; Adrada BE; Murthy RK; Damodaran S; DeSnyder SM; Brewster AM; Barcenas CH; Valero V; Whitman GJ; Schwartz-Gomez J; Mittendorf EA; Thompson AM; Helgason T; Ibrahim N; Piwnica-Worms H; Moulder SL; Arun BK
    J Clin Oncol; 2020 Feb; 38(5):388-394. PubMed ID: 31461380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Talazoparib for BRCA-mutated advanced breast cancer.
    Gunjur A
    Lancet Oncol; 2018 Oct; 19(10):e511. PubMed ID: 30146245
    [No Abstract]   [Full Text] [Related]  

  • 17. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib for the treatment of breast cancer.
    Griguolo G; Dieci MV; Guarneri V; Conte P
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):519-530. PubMed ID: 29582690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
    Mittra A; Coyne GHOS; Zlott J; Kummar S; Meehan R; Rubinstein L; Juwara L; Wilsker D; Ji J; Miller B; Navas T; Ferry-Galow KV; Voth AR; Chang TC; Jiwani S; Parchment RE; Doroshow JH; Chen AP
    Cancer Chemother Pharmacol; 2024 Mar; 93(3):177-189. PubMed ID: 38010394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
    Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.